.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Teva
Cipla
Dow
Baxter
Boehringer Ingelheim
Chubb
Colorcon
QuintilesIMS
Harvard Business School

Generated: June 27, 2017

DrugPatentWatch Database Preview

Histrelin acetate - Generic Drug Details

« Back to Dashboard

What are the generic sources for histrelin acetate and what is the scope of histrelin acetate freedom to operate?

Histrelin acetate
is the generic ingredient in three branded drugs marketed by Endo Pharm and Shire, and is included in three NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Histrelin acetate has three patent family members in three countries.

There are two drug master file entries for histrelin acetate. One supplier is listed for this compound.

Summary for Generic Name: histrelin acetate

Tradenames:3
Patents:2
Applicants:2
NDAs:3
Drug Master File Entries: see list2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list12
Clinical Trials: see list903
Patent Applications: see list3,611
Therapeutic Class:Hormonal Agents, Suppressant (Pituitary)
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:histrelin acetate at DailyMed

Pharmacology for Ingredient: histrelin acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire
SUPPRELIN
histrelin acetate
INJECTABLE;INJECTION019836-001Dec 24, 1991DISCNNoNo► Subscribe► Subscribe
Endo Pharm
SUPPRELIN LA
histrelin acetate
IMPLANT;SUBCUTANEOUS022058-001May 3, 2007RXYesYes8,062,652► Subscribe ► Subscribe
Endo Pharm
VANTAS
histrelin acetate
IMPLANT;SUBCUTANEOUS021732-001Oct 12, 2004RXYesYes► Subscribe► Subscribe
Shire
SUPPRELIN
histrelin acetate
INJECTABLE;INJECTION019836-003Dec 24, 1991DISCNNoNo► Subscribe► Subscribe
Shire
SUPPRELIN
histrelin acetate
INJECTABLE;INJECTION019836-002Dec 24, 1991DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: histrelin acetate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shire
SUPPRELIN
histrelin acetate
INJECTABLE;INJECTION019836-002Dec 24, 19914,244,946► Subscribe
Endo Pharm
SUPPRELIN LA
histrelin acetate
IMPLANT;SUBCUTANEOUS022058-001May 3, 20075,266,325► Subscribe
Endo Pharm
VANTAS
histrelin acetate
IMPLANT;SUBCUTANEOUS021732-001Oct 12, 20045,266,325► Subscribe
Shire
SUPPRELIN
histrelin acetate
INJECTABLE;INJECTION019836-001Dec 24, 19914,244,946► Subscribe
Endo Pharm
SUPPRELIN LA
histrelin acetate
IMPLANT;SUBCUTANEOUS022058-001May 3, 20075,292,515► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: histrelin acetate

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2006009801► Subscribe
Canada2570960► Subscribe
European Patent Office1773293► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Julphar
Accenture
Merck
Healthtrust
Moodys
Johnson and Johnson
Queensland Health
Citi
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot